Last reviewed · How we verify
NCT05831488: VERVE
Assessing the Accuracy of Seismofit® as an Estimate of VO2 Peak in Patients With Hepato-pancreato-biliary, Colorectal, and Gastro-oesophageal Cancer
trial testing Non-Interventional in Hepato-Biliary Carcinoma in Situ Nos in 35 participants. Status unknown.
1 October 2023
Quick facts
| Lead sponsor | Royal Marsden NHS Foundation Trust |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 35 |
| Start date | 1 March 2023 |
| Primary completion | 1 October 2023 |
| Estimated completion | 1 March 2024 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Non-Interventional
Conditions studied
- Hepato-Biliary Carcinoma in Situ Nos — all drugs for Hepato-Biliary Carcinoma in Situ Nos →
- Pancreatic Cancer — all drugs for Pancreatic Cancer →
- Colorectal Cancer — all drugs for Colorectal Cancer →
- Gastric Cancer — all drugs for Gastric Cancer →
Sponsor
Royal Marsden NHS Foundation Trust
Who can join
18 and older, any sex, with Hepato-Biliary Carcinoma in Situ Nos or Pancreatic Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Our study aims to assess the relationship between the Seismofit® derived VO2 peak estimate and CPET-measured VO2 peak in patients who are having CPET as part of their preoperative workup. Our aim is to establish whether Seismofit® can be considered a cheaper, less resource intensive and better tolerated alternative to the CPET, or whether it might be useful as a screening tool to efficiently identify patients with exercise intolerance who may benefit from further characterisation by CPET.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Assessing the accuracy of Seismofit® as an estimate of preoperative maximal oxygen consumption in patients with hepato-pancreato-biliary, colorectal, and gastro-oesophageal cancer.
Tetlow N, Devendra P, Waiting J, Aresu M, et al · · 2025 · PMID 40248106 · DOI 10.1016/j.bjao.2025.100395
Verify or expand the search:
- PubMed search for NCT05831488
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Non-Interventional
Trials testing the same drug.
- NCT06412029 — Understanding and Enhancing Health-Related Social Needs (HRSN) Screening Among Community Oncology Practices · enrolling by invitation
- NCT05568459 — A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standa · active not recruiting
- NCT06527508 — Construct Validity and Intra-Observer Reliability of the SDQ · completed
- NCT05919511 — Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease · recruiting
- NCT05510908 — Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMC · completed
Other Royal Marsden NHS Foundation Trust trials
Trials by the same sponsor.
- NCT07407686 — Improving Engagement From Underserved Communities With Prostate Cancer Genetics Services · not yet recruiting
- NCT07243834 — Assessing a Digital Exercise Intervention for Health Outcomes and Engagement in Regular Exercise · NA · recruiting
- NCT06605833 — CARDiac Toxicity Following ImmunOtherapy Treatment for Melanoma · enrolling by invitation
- NCT07008742 — Feasibility Study of Tissue and Blood Collection in Oncogene-addicted and Neoadjuvantly Treated Non Small Cell Lung Canc · recruiting
- NCT06560905 — Preoperative Planning With PSMA-PET in Melanoma Surgery Trial · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05831488 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Royal Marsden NHS Foundation Trust
- Last refreshed: 26 April 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05831488.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing